BUZZ-US-listed shares of NewAmsterdam Pharma fall on planned $300 mln public offering

Reuters12-12
BUZZ-US-listed shares of NewAmsterdam Pharma fall on planned $300 mln public offering

** U.S-listed shares of drug developer NewAmsterdam Pharma NAMS.O fall as much as 5.8%; last down 4.7% at $24.95

** NAMS late Tuesday announced commencement of a $300 mln public offering of shares and pre-funded warrants

** Offering commenced after NAMS terminated up to $150 mln "at-the-market" stock sale agreement with TD Cowen

** Jefferies, Goldman Sachs, Leerink Partners, TD Cowen, Guggenheim Securities and William Blair are the joint book-running managers for the offering

** Stock also rose 41.4% on Tuesday after NAMS reported data from a late-stage study that showed its experimental drug significantly reduced levels of low-density lipoprotein cholesterol

** NAMS has 92.4 mln outstanding shares and a $2.42 bln market capitalization as of last close - LSEG data

** As of last close, NAMS shares had more than doubled YTD

(Reporting by Arasu Kannagi Basil in Bengaluru)

((ArasuKannagi.Basil@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment